First use of creatine hydrochloride in premanifest Huntington diseaseDescription
Huntington disease is a devastating autosomal dominant neurodegenerative disorder that typically manifests between ages 30 and 50 years. Promising high-dose creatine monophosphate trials have been limited by patient tolerance.
This is the first report of use of creatine hydrochloride in two premanifest Huntington disease patients, with excellent tolerability over more than 2 years of use.
- Understand of treatment outcomes with creatine hydrochloride in two premanifest Huntington disease patients
GP, GP Registrar, Specialist, Doctors in Training (DIT), Medical Student, International Medical Graduate, Overseas Trained Doctor
ACRRM - Fellow: 0.5 pts
ACRRM - Non Fellow: 0h : 30m
RACGP: 1 pt